The schizophrenia therapy market is very crowded, with multiple oral long-acting injectable (LAI) antipsychotic agents. Indeed, to gain a foothold in the market, differentiation from already established therapies is a primary requirement for the late-phase and recently approved therapies not specifically targeting schizophrenia subpopulations with high unmet need—including new oral atypical antipsychotics (e.g., Alkermes’s Lybalvi), new LAIs (e.g., Janssen’s paliperidone six-month depot, Teva’s TV-46000), and other agents with novel mechanisms of action (e.g., Sunovion / Sumitomo Dainippon Pharma / Otsuka’s ulotaront [SEP-363856], Karuna Therapeutics’ KarXT). Although the potential of therapies in development to treat the negative symptoms of schizophrenia or the cognitive impairment associated with schizophrenia (CIAS) remains to be seen in late-phase studies, some agents had promising results in mid-phase clinical studies and could earn blockbuster sales, such as Acadia Pharmaceuticals’ pimavanserin and Boehringer Ingelheim’s BI 425809.
Questions Answered
- What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
- What percentage of diagnosed lifetime prevalent schizophrenia patients receive drug treatment? How large are the schizophrenia subpopulations with negative symptoms or cognitive impairment?
- What are the greatest areas of unmet need? Which late-phase therapies have the potential to fulfill these needs?
- How will novel emerging therapies be positioned in the schizophrenia treatment algorithm?
Geographies: United States, EU5, Japan.
Primary research: 26 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms, negative symptoms, and cognitive impairment; drug-treated prevalence of schizophrenia by country.
Forecast: Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2031, segmented by brands / generics.
Emerging therapies: Phase III / PR: 11 drugs. Coverage of select Phase II and Phase I products.
Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement: Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold. Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Himanshu Jain, M.S. Pharm.
Himanshu Jain, M.S.(Pharm.), Senior Manager, CNS and Ophthalmology. He has authored content for psychiatry and ophthalmology indications, including forecasting markets for schizophrenia, depression, and dry eye disease. He has about 15 years of experience working in market research and consulting firms. He earned his master’s degree in Pharmacology & Toxicology from the National Institute of Pharmaceutical Education and Research and holds an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.
Riya Kanakhara
Riya Kanakhara, B.Tech., Associate Healthcare Research & Data Analyst, CNS and Ophthalmology. Ms. Kanakhara has substantial experience in market research and has produced competitive intelligence reports in multiple therapy areas, including oncology, ophthalmology, neurology, and psychiatry. She has also prepared post-conference reports for conferences such as the American Academy of Neurology. She holds a bachelor’s degree in biotechnology from Amity University in India.
Shayan Chakraborty
Shayan Chakraborty is a senior healthcare research and data analyst on the CNS/Ophthalmology Disorders team at Clarivate. In this role, he oversees the team’s syndicated research stream in neurology, with a core focus on migraine. He has several years of experience working in the pharmaceutical industry providing analytical support in various therapy areas, including oncology, vaccines, specialty pharma, and rare diseases.
Prior to joining Clarivate, he was an assistant manager at WNS Global Services, where he was responsible for providing analytical and forecasting support to Global Vaccine Business Insight partners for early-phase products. He holds a bachelor’s degree in biotechnology from West Bengal University of Technology and a master’s degree in biotechnology and biochemical engineering from the Indian Institute of Technology, Kharagpur. Currently, he is pursuing India’s first full-time online bachelor’s degree in data science and programming from the Indian Institute of Technology, Madras.